Prognostic scoring systems in MDS

Leukemia Research

Volumn 36, Issue 12, 2012, Pages 1463-1469

  Germing, Ulrich ^a   Kündgen, Andrea ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Myelodysplastic syndromes; Prognostic scoring systems (IPSS)

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; COMORBIDITY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG APPROVAL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; STANDARD; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION STUDY; WORLD HEALTH ORGANIZATION;

BIOLOGICAL MARKERS; BLOOD CELLS; BONE MARROW; HUMANS; KARYOTYPING; MYELODYSPLASTIC SYNDROMES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESEARCH DESIGN; RISK; SURVIVAL ANALYSIS;

EID: 84868190982     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.005     Document Type: Review

References (74)

1. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
2. Germing U., Aul C., Niemeyer C.M., Haas R., Bennett J.M. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 2008, 87:691-700.
3. Aul C., Gattermann N., Heyll A., Germing U., Derigs G., Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992, 6:52-59.
4. Aul C., Gattermann N., Germing U., Runde V., Heyll A., Schneider W. Risk assessment in primary myelodysplastic: validation of the Duesseldorf Score. Leukemia 1994, 8:1906-1913.
5. Nachtkamp K., Stark R., Neukirchen J., Kündgen A., Giagounidis A., Haas R., et al. Analysis of causes of death in 2297 patients with myelodysplastic syndromes. Data from the MDS registry. Leuk Res 2011, 35(Suppl. 1):60.
6. Neukirchen J., Blum S., Kuendgen A., Strupp C., Aivado M., Haas R., et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur J Haematol 2009, 83:477-482.
7. Varela B.L., Chuang C., Woll J.L., et al. Modifications in the classification of primary myelodysplastic syndromes by the addition of scoring system. Hematol Oncol 1985, 3:55-63.
8. Mufti G.J., Stevens J.R., Oscier D.G., et al. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Hematol 1985, 59:425-433.
9. Worsley A., Oscier D.G., Stevens J., et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Hematol 1988, 68:17-21.
10. De Rosa L., Montuoro A., Del Monte C. Myelodysplastic syndromes (MDS) with excess of blasts: identification of subgroups with different prognosis. Leuk Res 1987, 11(Suppl. 1):37.
11. Doll D.C., Taylor H.M., Yesus Y.W., et al. Myelodysplastic syndrome: prospective evaluation of fifty-one patients using the Dutcher scoring system. Acta Haematol 1989, 81:86-90.
12. Cassano E., Giordano M., Riccardi A., et al. Myelodysplastic syndromes: a multiparametric study of prognostic factors and proposed scoring system. Haematologica 1990, 75:141-145.
13. Goasguen J.E., Garand R., Bizet M., et al. Prognostic factors of myelodysplastic syndromes. A simplified 3-D scoring system. Leuk Res 1990, 14:255-262.
14. Rubio-Felix D., Giraldo P., Franco E., et al. Prognostic factors in myelodysplastic syndromes: analysis of five scoring systems. Hematol Oncol 1995, 13:139-152.
15. Maschek H., Gutzmer R., Choritz H., et al. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsy of 569 patients. Eur J Haematol 1994, 53:280-287.
16. Guerci A.-P., Feldmann L., Humbert J.-C., et al. Refractory anemia with excess of blasts: a multivariate analysis of prognostic factors in 91 patients and a simplified scoring system for predicting survival. Eur J Haematol 1995, 54:241-244.
17. Oguma S., Yoshida Y., Uchino H., et al. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Leuk Res 1995, 19:219-225.
18. Chevret S., Thomas G., Beaune R., et al. Prognosis scoring system in refractory anemia with excess of blast (RAEB). Leuk Res 1996, 21(Suppl. 1):6.
19. Souto E.X., Chauffaille M.L., Braga J.E. Myelodysplastic syndromes (MDS): prognostic factors and scoring systems. Leuk Res 1996, 21(Suppl. 1):35.
20. Tomonaga M., Fuchijani M., Matsuo T. Analysis of prognostic factors for low-risk MDS. A proposal for a new scoring system. Leuk Res 1997, 21(Suppl. 1):51.
21. Lataglia R., Breccia M., Betro P., et al. A simple clinical scoring system in refractory anemia with exess of blasts in transformation (RAEB-T). Leuk Res 1999, 23(Suppl. 1):178.
22. Sanz G.J., Sanz M.A., Vallespi T., et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic sydromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989, 74:395-408.
23. Morra E., Lazzarino M., Castello A., et al. Risk assessment in myelodysplastic syndromes: value of clinical, haematologic and bone marrow findings at presentation. Eur J Hematol 1990, 45:94-100.
24. Morel P., Hebbar M., Lai J.L., et al. Cytogenetic analysis has a strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993, 7:1315-1323.
25. Parlier V., van Melle G., Beris Ph., et al. Prediction of 18-month survival in patients with primary myelodysplastic syndrome. Cancer Genet Cytogenet 1995, 81:158-165.
26. Pfeilstöcker M., Reisner R., Nösslinger T., et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients form a single institution confirms importance of cytogenetics. Br J Haematol 1999, 106:455-463.
27. Toyama K., Ohyashiki K., Yoshida Y., et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993, 7:499-508.
28. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
29. Della Porta M.G., Malcovati L., Strupp C., Ambaglio I., Kuendgen A., Zipperer E., et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011, 96:441-449.
30. Onida F., Kantarjian H.M., Smitz T.L., et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002, 99:840-849.
31. Scott B.L., Wells D.A., Loken M.R., Myerson D., Leisenring W.M., Deeg H.J. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008, 112(October (7)):2681-2686.
32. Garcia-Manero G., Shan J., Faderl S., et al. A prognostic score for patients with lower risk myelodysplastic syndromes. Leukemia 2008, 22:538-543.
33. Kantarjian H., Obrien S., Ravandi F., et al. Proposals for a new risk model in myelodysplastic syndromes that accounts for events not considered in the original International prognostic scoring system. Cancer 2008, 113:1351-1361.
34. Tong W.G., Quintas-Cardama A., Kadia T., et al. Predicting survival of patients with hypocellular myelodysplastic syndromes. Cancer 2012, [E-published].
35. Naqvi K., Garcia-Manero G., Sardesai S., et al. Association of comorbidities with overall survival in myelodysplastic syndromes: development of a prognostic model. J Clin Oncol 2011, 29:2240-2246.
36. Greenberg P.L., Tuechler H., Schanz J., et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood. 2012, [Epub ahead of print].
37. Esperanza S., Jose C., Dolors C., et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011, 96:375-383.
38. Malcovati L., Germing U., Kuendgen A., DellaPorta M.G., Pascutto C., Invernizzi R., et al. Time dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
39. Kuendgen A., Strupp C., Aivado M., et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006, 24:5358-5365.
40. Noesslinger T., Tüchler H., Germing U., Sperr W.R., Krieger O., Haase D., et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 2010, 21:120-125.
41. Kao J.M., McMillan A., Greenberg P.L. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008, 83:765-770.
42. Germing U., Hildebrandt B., Pfeilstocker M., Nosslinger T., Valent P., Fonatsch C., et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005, 19:2223-2231.
43. van de Loosdrecht A.A., Westers T.M., Westra A.H., Dräger A.M., et al. Identification of distinct prognostic subgroups in low- and intermediate 1 risk myelodysplastic syndromes by flow cytometry. Blood 2008, 111:1067-1077.
44. Büsche G., Teoman H., Wilczak W., Ganser A., Hecker H., Wilkens L., et al. Marrow fibrosis predicts early fatal marrow failure in patients with MDS. Leukemia 2008, 22:313-322.
45. Bennett J.M. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000, 72:131-133.
46. Brunning R.S., Orazi A., Germing U., et al. Myelodysplastic syndromes/neoplasms, overview. WHO classification of tumours of haematopoietic and lympoid tissues 2008, IARC Press, Lyon. S.H. Swerdlow (Ed.).
47. Germing U., Gattermann N., Strupp C., et al. Validation of the WHO propsals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000, 24:983-992.
48. Germing U., Lauseker M., Hildebrandt B., Symeonidis A., Cermak J., Fenaux P., et al. Survival, prognostic factors, and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 2012, 26:1286-1292.
49. Gattermann N., Aul C., Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 1990, 74:45-52.
50. Garand R., Gardais J., Bizet M., et al. Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). Leuk Res 1992, 16:463-468.
51. Rosati S., Mick R., Stonys E., et al. Refractory cytopenia with multilineage dysplasia: further characterization of an "unclassifiable" myelodysplastic syndrome. Leukemia 1996, 10:20-26.
52. Pereira A., Nomdedeu M., Aguilar J.L., Belkaid M., Carrio A., Cobo F., et al. Transfusion intensity, not the cumulative red blood cell transfusion burder, determines the prognosis of patients with myelodysplastic syndromes on chronic transfusion support. Am J Hematol 2011, 8:245-250.
53. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007, 31(Suppl. 3):2-6.
54. Pfeilstöcker M., Tüchler H., Schönmetzler A., Nösslinger T., Pittermann E. Time changes in predictive power of established and recently proposed clinical cytogenetical and comorbidity scores for myelodysplastic syndromes. Leuk Res 2012, 36:132-139.
55. Bernasconi P., Klersy C., Boni M., Cavigliano P.M., Giardini I., ROcca B., et al. Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution. Ann Hematol 2010, 89:545-551.
56. Zohren F., Strupp C., Kuendgen A., et al. Characteristics of disease progression in 3213 patients with myelodysplastic syndrome. Blood 2008, 112:930. [abstract].
57. Schanz J., Steidl C., Fonatsch C., Pfeilstöcker M., Nösslinger T., Tuechler H., et al. Coalesced multicentric analysis of 2351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011, 29:1963-1970.
58. Schanz J., Tüchler H., Solé F., Mallo M., Luño E., Cervera J., et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an International Database Merge. J Clin Oncol 2012, 30:820-829.
59. Zipperer E., Pelz D., Nachtkamp K., Kuendgen A., Strupp C., Gattermann N., et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009, 94:729-732.
60. Sperr W.R., Wimazal F., Kundi M., et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCTCI and CCI in a core dataset of 419 patients of the Austrian MDS Study group. Ann Oncol 2010, 21:114-119.
61. Kündgen A., Lee J.H., Matsuda A., Lee K.H., Lee J.H., Gattermann N., et al. Differences in clinical characteristics and prognostic features between patients with myelodysplastic syndromes (MDS) from Korea, Japan, and Germany. Blood 2010, 116:785. [abstract].
62. Germing U., Kundgen A., Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004, 45:1311-1318.
63. Such E., Cervera J., Costa D., et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011, 96:375-383.
64. Komrokji R.S., Corrales-Yepez M., Najla A.A., et al. Validation of the MD Anderson prognostic risk model for patients with myelodysplastic syndromes. Cancer 2012, 118:2659-2664.
65. Zipperer E., Graef K., Kündgen A., Hildebrandt B., Haas R., Gattermann N., et al. Validation of the "Texas Score" for the prognostication of patients with myelodysplastic syndromes. Leuk Res 2011, 35(Suppl. 1):130.
66. Matsuda A., Jinnae I., Yagasaki F., et al. Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 1998, 12:482-485.
67. Thol F., Friesen I., Damm F., Yun H., Weissinger E.M., Krauter J., et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011, 29:2499-2506.
68. Bejar R., Stevenson K., Caughey B., et al. Validation of a prognostic model and the impact of SF3B1, DNMT3A, and other mutations in 289 genetically characterized lower risk MDS patient samples. Blood 2011, 118. 443-443.
69. Bejar R., Stevenson K., Abdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364(26):2496-2506.
70. Aivado M., Spentzos D., Germing U., Alterovitz G., Meng X.Y., Grall F., et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci 2007, 104:1307-1312.
71. Thiel A., Beier M., Ingenhag D., Servan K., Hein M., Moeller V., et al. Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance. Leukemia 2011, 25:387-399.
72. Nachtkamp K., Kündgen A., Strupp C., Giagounidis A., Kobbe G., Gattermann N., et al. Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 2009, 33:1024-1028.
73. Alessandrino E.P., Della Porta M.G., Bacigalupo A., Van Lint M.T., Falda M., Onida F., et al. Gruppo Italiano Trapianto di Midollo Osseo (GITMO), WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008, 112:895-902.
74. Hellström-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Brit J Haematol 2003, 120:1037-1046.